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The modulation of serotonin (5-HT) release by opioid receptors in the hippocampus of the awake, unrestrained rat was evaluated by use of in 
vivo microdialysis. The hippocampus was perfused with Ringer's solution (2/~l/min), and extracellular levels of 5-HT and its major metabolite, 
5-hydroxyindoleacetic acid (5-HIAA) were estimated by assaying their concentration in the dialysate by HPLC-ECD. Addition of potassium (K ÷, 
60 and 120 mM) to the perfusate evoked a concentration-dependent release of 5-HT, but did not alter extracellular 5-HIAA levels. Co-perfusion 
of morphine (0.1 to 10 ~M) with K + (120 mM) produced a concentration-dependent reduction of 5-HT release. Naltrexone (0.03 to 3 mg/kg, 
i.p.), a relatively selective/z-opioid receptor antagonist, blocked in a dose-dependent manner the morphine (10/zM)-induced inhibition of 5-HT 
release. Naltrexone alone did not alter significantly either extracellular 5-HT levels or the release of 5-HT evoked by K +. Neither co-perfusion 
with [D-Pen 2, D-PenS]-enkephalin (DPDPE, 1 to 10 /zM), an agonist selective for 8-opioid receptors, nor with U-69593 (10 /zM), an agonist 
selective for K-opioid receptors, modified the K + (120 mM)-evoked release of 5-HT. These findings indicate that p~-opioid receptors modulate 
the physiological release of 5-HT from serotonergic neurons in the rat hippocampus. 
INTRODUCTION 
Specific opioid receptors  appear  to modula te  the 
release of  specific neurot ransmit ter  substances in the 
central  nervous system. For  example, st imulation of  
~-opioid receptors  inhibits both K÷-st imulated and 
electrically st imulated release of  [3H]dopamine from 
rat striatal slices, but  does not inhibit the release of  
[taC]acetylcholinetS'16't9. In contrast ,  st imulation of  K- 
opioid receptors  in rat striatal slices inhibits the neu- 
ronal release of  [taC]acetylcholine, but  not that  of  
[3H]dopamine.  In rat cerebral  cortical slices, neuronal  
release of  [3H]norepinephr ine  has been  shown to be 
modula ted  by/x-opio id  receptors  16'19. 
The  role of  opioid receptors  in the regulation of  
serotonin (5-HT) release, however, remains unclear  at 
this time. Hagan  and Hughes  6 repor ted  that  opioid 
receptors  were not involved in the electrically stimu- 
lated release of  [3H]5-HT from rat cortical slices. De-  
war et al. 3 also were unable  to demonst ra te  opioid 
receptor  mediat ion of  K÷-st imulated release of  [3H]5- 
H T  from slices of  rat globus pallidus. In contrast,  
Passarelli and Costa t7 repor ted  that stimulation o f / z - ,  
3- and ~c-opioid receptors  in rat h ippocampal  slices 
inhibited K÷-st imulated release of  [3H]5-HT. In this 
latter study, [D-Ala 2, N-Me-Phe  4, GlyS-ol]enkephalin 
( D A M G O ) ,  a /z-opioid receptor  agonist, and D P D P E ,  
~-opioid receptor  agonist, were more  efficacious than 
U50488H ( trans-3,4-dichloro-N-methyl-N-[2-(1-pyrro-  
l idinyl)-cyclohexyl]benzene-actamine), a K-opioid re- 
ceptor  agonist, as inhibitors of  [3H]5-HT release. All of  
these studies have involved the use of  in vitro prepara-  
tions, and the results of  such studies might be influ- 
enced significantly by the nature  of  the artificial envi- 
ronment  in which they must  be conducted.  
In vivo microdialysis, in combinat ion with high per- 
formance  liquid chromatography  (HPLC)  and electro- 
chemical  detect ion (ECD),  permits  the study of  neuro-  
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transmitter release from neurons in brains of awake, 
unrestrained animals. Using this approach, we have 
recently shown that a2-adrenergic receptors on hip- 
pocampal serotonergic nerve terminals regulate K ÷- 
stimulated release of 5-HT in vivo 24. These findings 
are in accordance with those reported with hippocam- 
pal brain slices in vitro 12. The objective of the present 
study was to determine whether opioid receptors regu- 
late 5-HT release from serotonergic neurons in the rat 
hippocampus. The hippocampus was chosen because it 
is an area of the rat brain innervated by serotonergic 
neurons t3 and because radioligand binding studies have 
demonstrated the presence of /z-, x- and 8-opioid 
receptor binding sites TM. To evaluate opioid receptor 
function three agonists were used, morphine (/z-selec- 
tive), DPDPE (fi-selective) and U-69593 (5a,7a,8/3- 
( - )-N-methyl-N-[7-(1 -pyrrolidinyl)- 1 -oxaspiro(4,5 )dec- 
8-yl]phenyl-benzeneacetamine, r-selective). In addi- 
tion, the actions of naltrexone, an antagonist similar to 
naloxone in its selectivity for/z-opioid receptors, was 
studied. 
MATERIALS AND METHODS 
Animals 
The experiments were performed on male, Wistar rats (250-350 g 
and 8 to 12 weeks old, Shizuoka Laboratory Animal Center, Hama- 
matsu, Japan). The animals were housed in a room with a 12-h light 
(07.00-19.00)-dark (19.00-07.00) cycle and were given free access to 
food and water. 
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Brain microdialysis 
Rats were anesthetized with ketamine (100 mg/kg, i.p.), and an 
8-mm dialysis-probe guide cannula was stereotaxically implanted into 
the hippocampus so that a concentric dialysis probe with a 3-mm tip 
would be positioned with its tip at the following co-ordinates with 
relation to the bregma and dural surface of the brain18: rostral-caudal, 
- 5 . 8  mm; lateral -4 .8  mm. ventral -7 .0  mm, from the bregma and 
the dural surface. The guide cannula was attached to the skull with 
dental cement. Two days after the surgical implantation of the guide 
cannula, a dialysis probe was inserted into the guide cannula and the 
probe was then perfused continuously (2 p.l/min) with Ringer's 
solution of the following composition (raM): NaCl 147, KCI 4, CaCl 2 
2.3, pH 6.4. The perfusion medium was delivered by a 1-ml syringe 
mounted on a microinfusion pump (CMA/100, Carnegie Medicin, 
Stockholm, Sweden) through a coiled teflon tube and returned 
through a similar coiled teflon tube that allows the rat to move about 
freely. In preliminary experiments it was found that the levels of 
5-HT in the dialysate were high immediately after insertion of the 
probe but decreased to constant values within 3 h. Therefore, collec- 
tion of the perfusate was started 3 h after implantation of the probe. 
Nine successive 40-~1 samples were collected at 20-min intervals in 
vials that contained 10 ~l of ice-cold acetic acid (0.05 N). The 
samples were injected immediately into a high performance liquid 
chromatograph. 
To stimulate 5-HT release, KCl (either in a concentration of 60 
or 120 mM) was administered through the perfusion system for two 
10-min periods of time. In order to maintain the osmolarity of the 
perfusion fluid when either 60 or 120 mM KCI was added, the 
existing NaC1 was replaced with the KCI. The first administration of 
KCI (S1, 40-50 min, Figs. 2 and 3) occurred at the beginning of the 
fourth 20-min collection period and the second administration at the 
beginning of the seventh ($2, 100-110 min, Figs. 2 and 3) collection 
period. In control experiments, the S 2 / S  1 ratio was found to be 
approximately 1.0 under these experimental conditions. Morphine 
and other opioid receptor agonists were added to the perfusion 
solution at the time of the second administration of KC1 ($2). 
Naltrexone, an opioid receptor antagonist, was injected intraperi- 
toneally 20 min prior to the second KCl-perfusion period ($2). At 
the end of each experiment, the rat was sacrificed, and its brain was 
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Fig. 1. Chromatograms of samples of dialysate collected during perfusion of the rat hippocampus with Ringer's solution under basal condlUons 
(A), after K + stimulation (120 mM, B) or after K + stimulation in the presence of morphine (1 /~M, C). HPLC-ECD was carried out under the 
following conditions: flow rate, 0.5 ml/min; pressure, 40 kg/cm2; applied potential, 600 mV, and cell current, 3.0 nA. Simultaneous tracings at 
various levels of amplification were made in order to measure peaks for 5-HT and 5-HIAA. Note that K + stimulation increases the 5-HT, but 
not the 5-HIAA peak (B) whereas co-perfusion with morphine (1 /~M) reduces markedly the release of 5-HT induced by K +. 
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removed, sectioned and examined histologically to determine the 
precise insertion site of the dialysis probe. 
Determination of 5-HT and 5-HIAA 
5-HT and its metabolite, 5-HIAA, were separated and measured 
by use of a HPLC system coupled to an ECD system as described 
previously hi. The HPLC-ECD system consisted of a pump (P-500, 
Irika Kogyo, Kyoto, Japan) coupled to a reversed-phase column 
(EiCOM, MA-50DS, ODS, 5/*m particle size) and an electrochemi- 
cal detector (Irika, E-502). Shown in Fig. 1 are typical chro- 
matograms obtained with samples of dialysate collected before (Fig. 
1A) and after the administration of KCI, 120 raM, (Fig. 1B) or after 
the simultaneous administration of KCI, 120 mM, and morphine, 1 
~M, (Fig. 1C). Note that morphine produces a peak that does not 
overlap with those peaks produced by either 5-HT or 5-HIAA. 
Drugs 
The following compounds were used: 5-hydroxytryptamine creati- 
nine sulphate (Sigma Chemical Co. Ltd., St. Louis, MO, USA), 
morphine sulphate (Takeda Pharmaceutical Co., Osaka, Japan), nal- 
trexone hydrochloride (DuPont Pharmaceuticals, Garden City, NY, 
USA), [D-Pen 2, o-Pen-S]-enkephalin (Sigma), U-69593 (The Upjohn 
Co., Kalamazoo, MI, USA). and ketamine hydrochloride (Sankyo Co. 
Ltd., Tokyo, Japan). 
Calculations and statistical analysis 
5-HT in dialysates is expressed as a percentage of the absolute 
amount of 5-HT in the dialysate collected during the third 20-min 
collection period, i.e. the period immediately before addition of KCI 
to the perfusate. The amount of 5-HT released during K + stimula- 
tion is expressed as the amount in the dialysate collected during the 
fourth collection period (S 1) less the average of the amounts col- 
lected during the third and fifth collection periods or the amount 
collected during the seventh collection period (S 2) less the average 
of the amounts collected during the sixth and eighth collection 
periods. In vitro recoveries for some microdialysis probes were 
measured in order to determine the recovery efficiency of the probe 
membranes. To measure recovery, probes were placed in Ringer's 
solution that contained both 5-HT, 100 pg//xl, and 5-HIAA, 100 
pg//zl, and perfused at a flow rate of 2/zl /min at 37+ 1 °C. Mean in 
vitro recoveries (the concentrations of the 5-HT or 5-HIAA in the 
dialysate expressed as a percentage of the concentrations of these 
compounds outside of the dialysis probe)+S.E.M, of 8 determina- 
tions were 14.9_+ 2.7% for 5-HT and 11.7_+ 1.9% for 5-HIAA. 
All results are given as means+_S.E.M. Statistical comparisons 
were carried out using analysis of variance followed by Student's 
t-test. Values of P less than 5% were considered significant. 
R E S U L T S  
Effect of  K + on 5-HT release 
W h e n  i n t r o d u c e d  in to  t he  p e r f u s i o n  buf fe r ,  KCI 
i n c r e a s e d  the  c o n c e n t r a t i o n  in t he  d ia lysa te  o f  5 - H T ,  
bu t  no t  tha t  o f  5 - H I A A ,  in a c o n c e n t r a t i o n - d e p e n d e n t  
m a n n e r  (Fig.  2). T h e  m e a n  basa l  o u t p u t  o f  5 - H T  f r o m  
s e r o t o n e r g i c  n e u r o n s  in t he  rat  h i p p o c a m p u s  was  18.0 
_+ 1.9 f m o l / 4 0  t*l o f  d ia lysa te  and  tha t  o f  5 - H I A A  was  
4.6 _+ 0.8 p m o l / 4 0 / z l  o f  d ia lysa te .  KC1 was  i n t r o d u c e d  
into  t he  p e r f u s i o n  m e d i u m  for  10-min  p e r i o d s  at t he  
b e g i n n i n g  of  t he  f o u r t h  (S ] )  and  of  s e v e n t h  (S  2) 20-min  
co l l ec t i on  pe r iods .  T h e  m e a n  i nc r ea se  in 5 - H T  in t he  
d ia lysa te  wi th  60 m M  KCI was 80.3 _+ 30 .1% o v e r  basa l  
o u t p u t  levels  d u r i n g  S~ and  61.9_+ 11.2% d u r i n g  S 2 
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Fig. 2. Effects of low (60 mM) and high (120 mM) KCI upon 
extracellular 5-HT (A) and 5-HIAA (B) in rat hippocampus during in 
vivo microdialysis. Ordinate: amount of 5-HT or 5-HIAA in dialysate 
expressed as a percent of the amount in the third collection period, 
the period immediately before the first administration of KCI. Ab- 
scissa: time beginning with the first and ending with the ninth 
collection period. Dialysates were collected starting 180 min after 
insertion of the dialysis probe. S t and $2, 10-min periods during 
which the concentration of KCI was increased in the Ringer's perfu- 
sion buffer. Open circles, 60 mM KCI; solid circles, 120 mM KCI. 
Each point represents the mean of 4-5 experiments. Vertical bars 
represent the S.E.M. 
m e n t s  was  1.07 _+ 0.31. T h e  m e a n  i n c r e a s e  in 5 - H T  in 
t he  d ia lysa te  wi th  120 m M  KC1 was  241.6 _+ 36 .2% o v e r  
basa l  o u t p u t  levels  d u r i n g  SI and  260.8 _+ 64 .6% d u r i n g  
S 2 (Fig.  2A,  n = 4). T h e  m e a n  $2/S  l ra t io  in t h e s e  
e x p e r i m e n t s  was  1.05 +_ 0.17. N e i t h e r  c o n c e n t r a t i o n  o f  
KCI  c a u s e d  an a p p r e c i a b l e  c h a n g e  in 5 - H I A A  levels  
o v e r  basa l  o u t p u t  va lues  d u r i n g  e i t h e r  S~ or  S 2 (Fig.  
2B). A l t h o u g h  b o t h  c o n c e n t r a t i o n s  o f  KC1 gave  S z / S  ~ 
ra t ios  c lose  to unity,  t he  h i g h e r  c o n c e n t r a t i o n  o f  KC1 
was  c h o s e n  for  e x p e r i m e n t s  w i th  t h e  o p i o i d  agonis ts ,  
m o r p h i n e ,  D P D P E  and  U-69593 ,  and  wi th  n a l t r e x o n e  
s ince  wi th  this  c o n c e n t r a t i o n  t h e r e  was  less var iabi l i ty  
wi th in  ind iv idua l  an ima l s  and  a m o n g  d i f f e r e n t  an imals .  
Effect o f  opioid agonists on K +-evoked 5-HT release in 
the hippocampus 
M o r p h i n e ,  bu t  no t  D P D P E  or  U-69593,  i nh ib i t ed  










$1 mm s 2 mm 
0 20 40 60 80 100 120 1 4 0 1 6 0  
time (min) 
Fig. 3. Inhibition by morphine of hippocampal 5-HT release elicited 
by KCI, 120 raM. Antagonism by naltrexone. Experimental condi- 
tions were the same as in Fig. 2A. Open circles, control experiments. 
Solid circles, morphine, 10/zM, co-perfused with the second admin- 
istration of KC1 ($2); solid triangles, rats were treated with naltrex- 
one, 3 mg/kg, i.p. 20 min before co-perfusion of morphine and KC1 
($2). Each point represents the mean of 4-6 determinations. Verti- 
cal bars represent the S.E.M. 
perfusion medium simultaneously with the second 
stimulation with KCI (Sz). Morphine, an agonist rela- 
tively selective for /x-opioid receptors, inhibited 5-HT 
release in concentrations that ranged from 0.1 to 10 
~ M  (Figs. 3 and 4A). At a concentration of 0.1 /xM, 
morphine produced a 20.8 + 8.6% inhibition of release 
whereas at a concentration of 10 /zM the inhibition of 
release was nearly total (89.3 + 8.0%). When co-per- 
fused with KC1 at concentrations of 1 and 10 t~M, 
DPDPE,  an agonist highly selective for ~-opioid recep- 
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Fig. 4. Concentration-dependent effects of morphine on K+-evoked 
release of 5-HT (A) and antagonism by naltrexone of the effects of 
morphine, 10 IzM, on K+-evoked release of 5-HT (B) during in vivo 
microdialysis of the rat hippocampus. Ordinate: S 2 / S  1 ratios. Ab- 
scissa: concentrations of either morphine (A) or naltrexone (B). In 
some experiments (B), rats were injected intraperitoneally with vari- 
ous doses of naltrexone 20 min before co-perfusion of morphine and 
KCI ($2). Each point represents the mean of 4-6 determinations. 
Vertical bars represent the S.E.M. 
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TABLE I 
Effects of  DPDPE and U69593 on the K +-evoked release of 5-HT 
The opioid agonist was administered simultaneously with the second 
administration of KCI ($2). Each value represents the mean of n 
experiments _+ S.E.M. 
Experimental group Ratio (S 2 / S  1) n 
Control 1.05 _+ 0.17 4 
DPDPE 1 p~M 0.94_+0.09 4 
DPDPE 10/zM 1.07_+0.22 7 
U-69593 10/xM 1.04 _+ 0.20 4 
Similarly, U-69593, an agonist highly selective for K- 
opioid receptors, caused no inhibition of release when 
co-perfused with KC1 at the high concentration of 10 
t~M during S 2 (Table I). None of the three agonists, 
when administered without the concomitant adminis- 
tration of KCI, altered the spontaneous release of 
5-HT. These results suggest that the modulation by 
opioids of neuronal 5-HT release in the rat hippocam- 
pus is mediated solely by/z-opioid receptors. 
Antagonism by naltrexone of the morphine-induced inhi- 
bition of 5-HT release 
To determine further whether the inhibitory actions 
of morphine on 5-HT release were mediated by opioid 
receptors, the actions of morphine were determined in 
rats treated with naltrexone, an opioid antagonist rela- 
tively selective for /.L-opioid receptors, in doses that 
ranged from 0.03 to 3 mg/kg.  No concentration of 
naltrexone caused a change in the release of 5-HT 
during the period immediately prior to the co-perfu- 
sion of morphine with KCI ($2). Pretreatment with 
naltrexone did, however, prevent the inhibition of 5-HT 
release by morphine, 10 /zM, in a concentration-de- 
pendent manner (Figs. 3 (solid triangles) and 4B). The 
response to morphine was almost completely blocked 
by naltrexone, 3 mg/kg.  These observations are consis- 
tent with the hypothesis that morphine inhibits hip- 
pocampa! 5-HT release by acting at a /z-opioid recep- 
tor. 
DISCUSSION 
In the present study K + evoked large increases in 
extracellular 5-HT levels in the hippocampus of awake, 
unrestrained rats that were reflected by increased con- 
centrations of 5-HT in the dialysate during in vivo 
microdialysis. These increases in 5-HT were related to 
the concentration of KCI in the perfusion medium. 
During in vivo microdialysis of the hippocampus of 
chloralose-anesthetized rats, Sharp et al. 2° found simi- 
lar increases in extracellular 5-HT levels in the rat 
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hippocampus during electrical stimulation of the dorsal 
raphe nucleus. They demonstrated a good correlation 
between the frequency of electrical stimulation and the 
amount of 5-HT in the dialysate. These changes in 
5-HT levels were accompanied by small increases in 
the levels of 5-HIAA, the major metabolite of 5-HT in 
the brain, in the dialysates. 5-HIAA levels, however, 
were not correlated with the frequency of dorsal raphe 
nucleus stimulation or with 5-HT levels in the per- 
fusates. No changes in 5-HIAA levels occurred with 
K + stimulation of serotonergic neurons in the rat hip- 
pocampus in the present study despite large increases 
in 5-HT levels. These findings are consistent with the 
hypothesis that 5-HIAA levels reflect the turnover of 
the total 5-HT pool in the brain rather than the stimu- 
lated release of neuronal 5-HT 5'7. 
The action of morphine and other opioid agonists 
upon 5-HT release and upon 5-HIAA levels in various 
areas of the rat central nervous system is quite com- 
plex. A number of studies have suggested that either 
acute or chronic administration of morphine increases 
5-HT release and turnover in the rat brain 4'21'23. Matos 
et al. 9A° have reported that systemic administration of 
morphine has highly variable effects upon extracellular 
levels of 5-HT in the dorsal spinal cord as measured by 
in vivo microdialysis. These investigators reported that 
the systemic administration of morphine increased 
5-HT levels in only half of the rats studied and that 
DAMGO, administered intracerebroventricularly, in- 
creased 5-HT levels in only one third of the animals. 
They also found that 5-HIAA levels either decreased 
or remained unchanged after morphine administration. 
In contrast, Wood 22 found that morphine caused 
marked increase in the 5-HIAA content of the dorsal 
spinal cord. This action of morphine was dose-depen- 
dent and was antagonized by naioxone. This effect of 
morphine, however, was not shared by other opioid 
agonists that were known to stimulate either ~- or 
K-opioid receptors. The present study and a previous 
study 17 both found that opioid agonists inhibited the 
release of 5-HT during stimulation of serotonergic 
neurons in the rat hippocampus. Our study also found 
no effect of opioid agonists or of naltrexone upon 
hippocampal extracellular 5-HIAA levels. 
The present study suggests that /z-opioid receptors 
modulate K+-evoked release of 5-HT from serotoner- 
gic neurons in the rat hippocampus as determined by 
in vivo microdialysis. Morphine produced a concentra- 
tion-dependent inhibition of 5-HT release; and this 
action was antagonized by naltrexone, an antagonist 
relatively selective for ~-opioid receptors. Naltrexone 
alone had no effect upon the spontaneous release of 
5-HT which suggests that endogenous opioids do not 
exert a tonic regulation of 5-HT release under resting 
conditions. 
Autoradiographic studies have demonstrated the 
presence of binding sites for ligands relatively selective 
for 6- and K-opioid receptor sites, as well as binding 
sites for ~-opioid receptor-selective ligands, in the rat 
hippocampus 2,s. According to these reports, /z-opioid 
receptors predominate in this area of the rat brain, 
although 6- and K-opioid receptors are also present. In 
the present study, DPDPE, a 6-opioid receptor-selec- 
tive agonist, and U-69593, a K-opioid receptor-selective 
agonist, did not modify K+-evoked 5-HT release from 
neurons in the rat hippocampus even when adminis- 
tered in concentrations considerably higher than those 
required to produce maximum effects in other systems. 
Thus, despite the presence of 6- and K-opioid receptor 
binding sites in the rat hippocampus, the /z-opioid 
receptor would appear to be the primary opioid recep- 
tor involved in the regulation of 5-HT release in the rat 
hippocampus in vivo. 
Several investigators have reported that 5-HT re- 
lease is not modulated by opioid receptors in the rat 
brain. Hagen and Hughes 6 found the opioid agonists 
did not modify the electrically stimulated release of 
[3H]5-HT from rat cerebral cortical slices; and Dewar 
et al. 3 reported that opioid agonists did not modify 
K+-evoked release of 5-HT from slices of the rat globus 
pallidus. The differences between these observations 
and those of the present study might depend upon the 
areas of the brain that were studied. A similar regional 
difference in the regulation of 5-HT release by 
dopamine has been found. Benkirane et al. ~ reported 
that dopamine, through stimulation of a D I receptor, 
regulates the release of [3H]5-HT from neurons in the 
substantia nigra but not from neurons in the hippocam- 
pus. These investigators also reported no effect of 
opioid agonists upon [3H]5-HT release in the substan- 
tia nigra. 
In contrast to the present study, Passarelli and 
Costa ~v reported that/~-, 3- and K-agonists inhibited to 
various degrees the release of [3H]5-HT from slices of 
rat hippocampus. The effects of DAMGO in their 
study were those of a typical/z-opioid receptor agonist 
in that they were blocked competitively by naloxone. 
The modulation by DPDPE of [3H]5-HT release was 
unusual, however, in that naloxone produced a non- 
competitive antagonism of the inhibitory action of that 
drug. U-50488H, a K-opioid receptor-selective agonist, 
produced a small inhibition of K+-evoked [3H]5-HT 
release that was reversed by naloxone. The differences 
between the present study and that of Passarelli and 
Costa iv might be a result of differences in experimental 
approach. In the in vitro brain slice study, the concen- 
trations of [3H]5-HT used to label endogenous 5-HT 
stores (0.1 mM) were relatively large, and the [3H]5-HT 
might have been taken up by and subsequently re- 
leased from non-serotonergic cells, as well as from 
serotonergic neurons. Another possible explanation for 
the differences between the two studies might be that 
in vivo microdialysis, in which release of the actual 
endogenous neurotransmitter is measured, might re- 
veal a functionally significant population of receptors 
different from that population of receptors seen in 
vitro with brain slices labeled with an exogenous radi- 
oligand. Nevertheless, both studies demonstrate that in 
the rat hippocampus/.~-opioid receptors modulate 5-HT 
release. 
The current findings are consistent with the hypoth- 
esis that specific opioid receptors modulate the release 
of specific neurotransmitter substances in the central 
nervous system. ~-Opioid receptors appear to mediate 
the release of dopamine from the rat striatum 15'16'19. 
K-Opioid receptors appear to modulate the neuronal 
release of acetylcholine in the rat striatum 15'16. It has 
been suggested that /x-opioid receptors modulate the 
neuronal release of norepinephrine in the rat cerebral 
c o r t e x  16'19. The present study indicates that /z-opioid 
receptors also modulate the release of 5-HT in the rat 
hippocampus. 
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